Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 3/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573248 | 0.92 | TNK2 (0.38) | PDE4DERN1MAPTCA12CA1 | |
| SCHEMBL4511159 | 0.87 | ALDH1A1 (0.37) | PDE4DERN1MAPTKDM5BNPC1 | |
| SCHEMBL1931204 | 0.85 | RORC (0.43) | PDE4DMAPTKDM5BNPC1RAB9A | |
| SCHEMBL1573142 | 0.85 | MAP2K3 (0.38) | MAPTNPC1TNK2 | |
| SCHEMBL4511201 | 0.84 | KDM4E (0.35) | PDE4DMAPTKDM5BNPC1TNK2 | |
| SCHEMBL4509705 | 0.81 | PDE4D (0.38) | PDE4DERN1MAPTKDM5BNPC1 | |
| SCHEMBL1573291 | 0.79 | TNK2 (0.37) | PDE4DMAPTTNK2 | |
| SCHEMBL1932541 | 0.77 | RORC (0.50) | MAPT | |
| SCHEMBL4511181 | 0.77 | SYK (0.36) | PDE4DMAPTTNK2ADK | |
| SCHEMBL322566 | 0.75 | RORC (0.43) | MAPTPLAUCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | PDE4D 2003/4885ERN1 3615/4885MAPT 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.